LumaCyte has been named a 2025 BioTech Breakthrough Award winner, earning top honors in the category of Predictive Analytics Solution of the Year—a recognition that underscores the company’s leadership in nextgeneration biomanufacturing analytics. The annual BioTech Breakthrough Awards celebrate the most innovative companies, technologies, and products shaping the future of life sciences.
At the heart of this achievement is Laser Force Cytology™ (LFC), LumaCyte’s groundbreaking, labelfree singlecell analytical platform. As a cellular PAT solution, LFC provides realtime, inprocess monitoring that detects subtle phenotypic changes with extraordinary precision—without the need for antibodies or genetic labels. This capability transforms predictive analytics in bioprocessing, giving manufacturers earlier, clearer insight into critical quality attributes and driving greater manufacturing consistency and improved quality across cell and gene therapy, vaccine development, and advanced biologics production.
Winning the Predictive Analytics Solution of the Year award highlights how LumaCyte is reshaping the analytical landscape, moving the industry toward faster, more reliable, and more data rich decision making. As advanced biomanufacturing solutions continue to evolve, LumaCyte’s technology is setting a new standard for predictive precision, empowering teams to accelerate development timelines, elevate product quality, and strengthen alignment with regulatory frameworks that emphasize innovation and the use of Process Analytical Technology (PAT). By enabling earlier, data driven insight into product and process performance, LumaCyte supports more robust CMC strategies and helps developers mitigate risk with greater confidence.
This recognition marks an exciting milestone for LumaCyte and reinforces the company’s mission to advance global health through cuttingedge analytical innovation.
